The appropriate microbiological investigation of the
patient admitted with community-acquired pneumonia (CAP) remains a
contentious issue. Several arguments favor microbiological
investigation. First, the pathogen identified may be resistant to the
chosen empiric antibiotic therapy. Second, identification of the
pathogen may allow streamlining of antibiotic therapy, thereby reducing
cost and possibly reducing the development of antibiotic resistance.
Third, accurate epidemiologic data are required in order to design
appropriate empiric therapy.